The EGFR monoclonal antibody Cetuximab is approved by the FDA as a radiation sensitizer, alone or in combination with chemotherapy, for treating patients with recurrent or metastatic disease [36]. The gene discussed is EGFR; the disease is metastatic neoplasm.